I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Sellam, Gila
23
results:
Search for persons
X
Format
Online (23)
Mediatypes
Articles (Online) (12)
OpenAccess-fulltext (11)
Sorted by: Relevance
Sorted by: Year
?
1
Safety and efficacy of atezolizumab with rituximab and CHOP..:
Younes, Anas
;
Burke, John M.
;
Cheson, Bruce D.
...
Blood Advances. 7 (2023) 8 - p. 1488-1495 , 2023
Link:
https://doi.org/10.1182/..
?
2
A comparison of the prognostic performance of the Lugano 20..:
Kostakoglu, Lale
;
Martelli, Maurizio
;
Sehn, Laurie H.
...
eJHaem. 4 (2023) 4 - p. 1042-1051 , 2023
Link:
https://doi.org/10.1002/..
?
3
Baseline Total Metabolic Tumor Volume is Prognostic for Ref..:
Ruiz, Irene Canales
;
Martelli, Maurizio
;
Sehn, Laurie H.
...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) 8 - p. e804-e814 , 2022
Link:
https://doi.org/10.1016/..
?
4
Safety and efficacy of atezolizumab with obinutuzumab and b..:
Younes, Anas
;
Burke, John M.
;
Diefenbach, Catherine
...
Blood Advances. 6 (2022) 20 - p. 5659-5667 , 2022
Link:
https://doi.org/10.1182/..
?
5
Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refr..:
Topp, Max S.
;
Eradat, Herbert
;
Florschütz, Axel
...
Journal of Cancer Research and Clinical Oncology. 149 (2022) 2 - p. 811-817 , 2022
Link:
https://doi.org/10.1007/..
?
6
ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Elderly/Unf..:
Olszewski, Adam
;
Avigdor, Abraham
;
Babu, Sunil
...
Clinical Lymphoma Myeloma and Leukemia. 21 (2021) - p. S395-S396 , 2021
Link:
https://doi.org/10.1016/..
?
7
Total metabolic tumor volume as a survival predictor for pa..:
Kostakoglu, Lale
;
Mattiello, Federico
;
Martelli, Maurizio
...
Haematologica. 107 (2021) 7 - p. 1633-1642 , 2021
Link:
https://doi.org/10.3324/..
?
8
End-of-treatment PET/CT predicts PFS and OS in DLBCL after ..:
Kostakoglu, Lale
;
Martelli, Maurizio
;
Sehn, Laurie H.
...
Blood Advances. 5 (2021) 5 - p. 1283-1290 , 2021
Link:
https://doi.org/10.1182/..
?
9
Poster: ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Eld..:
Olszewski, Adam
;
Avigdor, Abraham
;
Babu, Sunil
...
Clinical Lymphoma Myeloma and Leukemia. 21 (2021) - p. S239 , 2021
Link:
https://doi.org/10.1016/..
?
10
A randomized, open-label, Phase III study of obinutuzumab o..:
Sehn, Laurie H.
;
Martelli, Maurizio
;
Trněný, Marek
...
Journal of Hematology & Oncology. 13 (2020) 1 - p. , 2020
Link:
https://doi.org/10.1186/..
?
11
Impact of bone marrow biopsy on response assessment in immu..:
Martin, Peter
;
Sellam, Gila
;
Sahin, Deniz
...
Blood Advances. 4 (2020) 8 - p. 1589-1593 , 2020
Link:
https://doi.org/10.1182/..
?
12
Physiological parameters after nonpharmacological analgesia..:
Gerull, Roland
;
Cignacco, Eva
;
Stoffel, Liliane
..
Acta Paediatrica. 102 (2013) 8 - p. , 2013
Link:
https://doi.org/10.1111/..
?
13
Safety and efficacy of atezolizumab with rituximab and CHOP..:
Younes, Anas
;
Burke, John M
;
Cheson, Bruce D
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125909/. , 2022
Link:
http://www.ncbi.nlm.nih...
?
14
Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refr..:
Topp, Max S
;
Eradat, Herbert
;
Florschütz, Axel
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931830/. , 2022
Link:
http://www.ncbi.nlm.nih...
?
15
End-of-treatment PET/CT predicts PFS and OS in DLBCL after ..:
Kostakoglu, Lale
;
Martelli, Maurizio
;
Sehn, Laurie H
...
Reproducció del document publicat a: https://doi.org/10.1182/bloodadvances.2020002690. , 2021
Link:
http://hdl.handle.net/24..
1-15